Search
Close this search box.

Brain Flow & Inflammation in ME, POTS & Long COVID

we see a PET (Positron Emission Tomography) scan in progress within a medical facility. The patient is lying on a narrow bed that is part of the PET scanning machine.

The study aims to explore the structural, neuro-vascular, and biochemical differences in the brains of individuals with ME/CFS, Long COVID, and POTS to elucidate the underlying pathology and identify potential targets for effective treatment strategies.

25-Day Metabolite Monitoring Study of ME/CFS Patients

The image is a visual representation of blood flow, depicting a stream of elements against a gradient background that suggests movement and fluidity.

The study aims to investigate the effects of supine vs upright exercise on cerebral blood flow, blood pressure, heart rate, and the presence of autoimmune antibodies in ME/CFS patients with orthostatic intolerance, compared to controls, to understand the underlying mechanisms and differences in symptom severity and post-exertional malaise.

Crash-Course: Studying PEM/flares in ME/CFS, PTLDS, Long COVID

a close-up of a finger with a drop of blood on it, against a white background.

The study aims to compare biological markers during mild symptoms and flare/PEM events in individuals with ME/CFS, alongside PTLDS and Long COVID patients, using finger-prick blood samples and continuous data from wearable sensors to understand symptom variability.

AusME Biobank Biomarker Project

a close-up of a gloved hand holding a test tube containing a blood sample. The test tube is labeled with barcode for identification and tracking purposes.

The study aims to utilize the Australian ME/CFS biobank for metabolomics analyses and other assays to identify potential biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, contributing to a comprehensive dataset for large-scale analysis.

Temporally Resolved Omics Tracking of ME/CFS

Woman researcher doing a blood test

This study seeks to understand the biological mechanisms driving the symptomatology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using metabolomic and lipidomic high-throughput analysis and high-frequency blood sampling over a 6.5 to 7.5 hour period conducted at two separate sites (Melbourne and Uppsala).